Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateTimeSourceHeadlineSymbolCompany
13/12/202123:30GlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
27/11/202107:25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NTLAIntellia Therapeutics Inc
22/11/202123:30GlobeNewswire Inc.Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)NASDAQ:NTLAIntellia Therapeutics Inc
10/11/202110:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
05/11/202122:30GlobeNewswire Inc.Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual MeetingNASDAQ:NTLAIntellia Therapeutics Inc
04/11/202122:42Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
04/11/202122:30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
28/10/202122:30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
21/10/202123:13Dow Jones NewsIntellia Gets FDA Orphan Designation for NTLA-2001 in ATTR AmyloidosisNASDAQ:NTLAIntellia Therapeutics Inc
21/10/202122:30GlobeNewswire Inc.Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisNASDAQ:NTLAIntellia Therapeutics Inc
20/10/202122:30GlobeNewswire Inc.Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual CongressNASDAQ:NTLAIntellia Therapeutics Inc
16/10/202110:03Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
14/10/202107:16Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
13/10/202122:01GlobeNewswire Inc.Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 TechnologyNASDAQ:NTLAIntellia Therapeutics Inc
12/10/202122:30GlobeNewswire Inc.Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual CongressNASDAQ:NTLAIntellia Therapeutics Inc
08/10/202108:41Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
06/10/202122:30GlobeNewswire Inc.Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
27/09/202121:30GlobeNewswire Inc.Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines ConferenceNASDAQ:NTLAIntellia Therapeutics Inc
26/09/202123:27TipRanksNTLA Stock Getting Ahead in Gene Editing RaceNASDAQ:NTLAIntellia Therapeutics Inc
24/09/202107:48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
16/09/202122:16Dow Jones NewsIntellia: FDA Accepts NTLA-5001 IND in Acute Myeloid LeukemiaNASDAQ:NTLAIntellia Therapeutics Inc
16/09/202121:30GlobeNewswire Inc.Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid LeukemiaNASDAQ:NTLAIntellia Therapeutics Inc
10/09/202107:39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
02/09/202109:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
02/09/202109:33Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
02/09/202109:31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
31/08/202121:30GlobeNewswire Inc.Intellia Therapeutics to Present at September Healthcare Investor ConferencesNASDAQ:NTLAIntellia Therapeutics Inc
26/08/202106:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
21/08/202108:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
07/08/202108:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA